Advertisement
Advertisement
U.S. markets open in 1 hour 25 minutes
Advertisement
Advertisement
Advertisement
Advertisement

SELLAS Life Sciences Group, Inc. (SLS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.2600+0.0500 (+2.26%)
At close: 04:00PM EDT
2.2600 0.00 (0.00%)
After hours: 05:27PM EDT
Advertisement
Sign in to post a message.
  • c
    ctrl+p_QE.exe
    https://twitter.com/SellasLife/status/1542141819361845253

    Need to see WAY more of this to get REGAL filled ASAP.
  • p
    peter
    SLS is teed up to be bought out. They have two promising assets, one nearing end of a phase three trial, with the lead investigator pusing for it's broader use prior approval and another that may be a best in class. I see take out price per share anywhere from $25-$50. If they go it alone, price per share could go substantially higher. Hence why i am long on SLS. Stay the course and have some faith.
  • C
    Camel boy
    Things are looking up
    Bullish
  • J
    Joe
    https://seekingalpha.com/article/4520830-bristol-myers-is-melting-up-again
    Gps Mentioned as a combo therapy to generate additional Opdivo Rev.
    Early results of this single-center trial included a median overall survival of 10.5 months from the time the earlier treatment was stopped. (Gps Opdivo) By comparison, patients with relapsed or refractory mesothelioma typically have an estimated overall survival of just 20-24 weeks.

    Six of the eight patients in this latest trial arrived in stage 3 or 4. The median survival time of 10.5 months is expected to improve as the trial progresses. Half of the patients were alive when results were released.
    Late last year, Bristol-Myers's broke out of a long-term range, and that break out is continuing. See the outlook for BMY stock here.
    Late last year, Bristol-Myers's broke out of a long-term range, and that break out is continuing. See the outlook for BMY stock here.
    seekingalpha.com
  • C
    Cured
    significant anti-leukemic effects had been reported at the 9-mg and 15-mg dose levels in patients with resistance to standard-of-care treatments, with 2 patients refractory to, or relapsed after, venetoclax (Venclexta) experiencing at least a 50% reduction in bone marrow blasts following GFH009 monotherapy.

    Notably, the 2 patients each previously had received 6 lines of therapy with venetoclax, chemotherapy, and experimental agent combinations.
    https://www.onclive.com/view/cdk9-inhibitor-gfh009-advances-in-phase-1-trial-in-relapsed-refractory-lymphoma-and-aml
    The novel and highly selective CDK9 inhibitor GFH009 demonstrated encouraging tolerability in patients with advanced, relapsed/refractory acute myeloid leukemia and lymphoma.
    The novel and highly selective CDK9 inhibitor GFH009 demonstrated encouraging tolerability in patients with advanced, relapsed/refractory acute myeloid leukemia and lymphoma.
    www.onclive.com
  • D
    Dangremaus
    The market price of the stock is basically reflecting cash on hand only at this point with no intrinsic value given to the drugs. This is such an interesting value play.
  • J
    Joe
    New 52 week low, come on pumpers, do something
  • j
    james
    The Chairman of MD Andersons Leukemia Dept is the lead investigator for the Gps Phase 3 Trial, he sees all the open label data and has Requested Expanded Access to Gps for additional AML Patient settings. 2 points: 1 most assuredly confirms Gps FDA Approval 2 An expanded off label patient market 5 times the initial $200M Secondary remission niche.
  • C
    Cured
    $XBI conversation
    $bmy growing revenue: Opdivo combination w Gps $sls “Opdivo is continuing to grow sales too, and it is reasonably probable that multiple combination therapies will be tested and approved in the coming years. For example, SELLAS Life Sciences (NASDAQ:SLS) recently reported updated data from a phase 1 trial of its galinpepimut-S drug in combination with BMY's Opdivo.”
    Bullish
  • C
    Cured
    This was not in the PR -- Very Big Deal
    Notably, the 2 patients each previously had received 6 lines of therapy with venetoclax, chemotherapy, and experimental agent combinations.
  • C
    CS1001
    Looks like we going higher tomorrow too
    Bullish
  • C
    Cured
    Conducted the EU Gps Phase 3 Investigators conference yesterday https://www.mskcc.org/cancer-care/doctors/david-scheinberg
  • P
    P509$
    $BMY is sizing up a Mesothelioma market value of $3- $4 B or $150 $200 Per share
    Bullish
  • S
    Stephens
    Picked up another 4k from the shorts at the close. iznice
  • M
    MauiRunner
    Last month SLS jumped from 2.10 to 3.60 about 80% up in a Week..........
  • J
    Joe
    Why is glsi up so much?
  • S
    Stephens
    Spent a lot time looking into the Jazz CPXX deal. It is a direct comp for Gps in AML Cr2 Same Market size. SLS shares are way undervalued. It explains why the many short ids toil away.
    To be sure there is little short volume out there, but what little remains is sure desperate at the bottom now.
    Bullish
  • C
    Cured
    SLS $MRK Joint Analysis
    Immunological data supporting the specific action of GPS in extending disease free survival and overall survival. These data are being analyzed by Merck and are going to presented in an 'upcoming medical conference'...so quite soon (July-August?) https://www.reddit.com/r/sellaslifesciences/comments/uy75zj/from_angelo_on_ovariancancer_combo_data_keytruda/
    Bullish
  • C
    Cured
    No dose limiting tox - None. up to 22.5 mg now. A partial Response at 9 mg for a patient who was refractory, ie metastatic malignancy - growing cancer after 3 lines, is unheard of.
    DLT's were the only reason previous CDK9's were not developed further. The dr's at MD A running SLS's Gps trials, also running the Genfleet GFH009, must have given SLS some indication of the great efficacy. IMO
    Bullish
  • S
    Stephens
    Spent a lot time looking into the Jazz CPXX deal. It is a direct comp for Gps in AML Cr2 Same Market size. SLS shares are way undervalued. It explains why all the short id toil away here.
Advertisement
Advertisement